WO2005075453A1 - リンカー化合物及びリガンド複合体、並びにそれらの製造方法 - Google Patents
リンカー化合物及びリガンド複合体、並びにそれらの製造方法 Download PDFInfo
- Publication number
- WO2005075453A1 WO2005075453A1 PCT/JP2005/001726 JP2005001726W WO2005075453A1 WO 2005075453 A1 WO2005075453 A1 WO 2005075453A1 JP 2005001726 W JP2005001726 W JP 2005001726W WO 2005075453 A1 WO2005075453 A1 WO 2005075453A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- ligand
- general formula
- glc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
Definitions
- the present invention relates to a linker compound capable of immobilizing a sugar chain such as an oligosaccharide on a protein analysis support such as a surface plasmon resonance sensor chip, and a method of introducing a sugar chain into the linker compound.
- the present invention relates to a ligand complex, a ligand carrier, and a production method thereof.
- a surface plasmon resonance (hereinafter, referred to as SPR) method is known. That is, a ligand complex containing an oligosaccharide simulating a part of a sugar chain is immobilized on the sensor chip surface, and the oligosaccharide is immobilized on the sensor chip. Identify substances such as proteins that interact specifically with sugar. This allows a correct evaluation of the biological activity based on the structure of the oligosaccharide.
- the present inventors have obtained a linker compound having in its molecule a site that can be immobilized on the sensor chip surface and a site that can introduce an oligosaccharide chain.
- a ligand conjugate obtained by introducing one or two units of oligosaccharide chains is obtained. Then, by using this ligand complex, the oligosaccharide chain is ligated on the sensor chip. (See, for example, Patent Document 1, Non-Patent Document 1, etc.).
- Patent Document 1 JP-A-2003-836969 (published on March 19, 2003)
- Non-Patent Document 1 "The 79th Annual Meeting of the Nippon Dani Kaikai Lecture Proceedings II", The Nippon Dani Gakkai, March 15, 2001, p. 1042
- Patent Document 1 With the ligand conjugates described in Patent Document 1 and Non-Patent Document 1, it is possible to arrange oligosaccharide sugar chains two-dimensionally on the sensor chip surface, but the sequence is reproducible. The technical problem that it is difficult to obtain well remains.
- the oligosaccharide chain of one ligand conjugate has one unit or two units.
- the above-mentioned ligand conjugate is obtained by binding one or two oligosaccharide chains to one linker compound. Therefore, in order to observe the biological activity of the oligosaccharide chain, when arranging the ligand complex on the surface of the sensor chip, the concentration of the ligand complex is increased to assemble the sugar chains as ligands. It is necessary to assemble 3 or more oligosaccharide chains on the chip surface.
- the present invention has been made to solve the above-mentioned problems, and an object of the present invention is to control the distance between sugar chains on the surface of a sensor chip and arrange oligosaccharides two-dimensionally with good reproducibility.
- An object of the present invention is to provide a novel linker compound, a novel ligand complex in which a sugar molecule is introduced into the linker compound, a ligand carrier, and a method for producing these. Disclosure of the invention
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems. As a result, the present inventors have found that a surface plasmon resonance (SPR) sensor chip having a site into which three or more sugar molecules can be introduced, By using a novel linker compound having a site capable of binding to a support for protein analysis such as a carrier for affinity chromatography, a sugar molecule of 3 units or more can be reproducibly and two-dimensionally applied to the support. It has been found that they can be arranged.
- SPR surface plasmon resonance
- the other linker compound has a problem in that the length of the alkyl group that forms a part of the linker is not sufficient and the oligosaccharide chain to be immobilized is large because of the steric hindrance of the oligosaccharide chain.
- a metal sulfur bond is not formed efficiently.
- the present inventors further introduced an oligoethylene oxide group into a part of the linker to minimize non-specific hydrophobic interaction and to reduce the amount of non-specific hydrophobic interaction up to the disulfide group used for metal bonding.
- the present inventors have found that the length can be easily adjusted and a metal-sulfur bond can be efficiently formed, and the present invention has been completed.
- the linker compound according to the present invention has the general formula (1) [0015] [Formula 11]
- X has an aromatic amino group at a terminal and is in the main chain. It may have a carbon-nitrogen bond and have a structure that is a hyperbranched structure site comprising three or more hydrocarbon-derived chains.
- linker compound according to the present invention has the general formula (2)
- n is an integer of 1 or more and 6 or less
- X is a hydrocarbon having an aromatic amino group at a terminal and optionally having a carbon-nitrogen bond in a main chain.
- the derivative chain may have a structure that is a hyperbranched structure site containing three or more chains.
- the hydrocarbon-derived chain refers to a hydrocarbon chain composed of carbon and hydrogen, in which some carbon or hydrogen may be replaced by another atom or substituent. And That is, the hydrocarbon-derived chain has an aromatic amino group at a terminal, and a part of a carbon-carbon bond (C-C bond), which is a main chain structure of the hydrocarbon chain, has a carbon-nitrogen bond (C -N bond), carbon oxygen bond (CO bond), and amide bond (CO-NH bond).
- the linker compound has an aromatic amino group as a site into which a sugar molecule can be easily introduced. Since the aromatic amino group is contained in each hydrocarbon-derived chain, three or more units of sugar molecules can be introduced into the linker compound. It also has an S—S bond as a site that can be immobilized on the protein analysis support.
- three or more sugar molecules can be aggregated and introduced into the support via the linker compound.
- three or more sugar molecules can be arranged on the surface of the support with good reproducibility. This makes it possible to observe the interaction between the sugar molecule and the protein on the surface of the support, and to evaluate the biological activity of the sugar molecule with good reproducibility.
- the linker compound has an oligoethylene dioxide group in a part of the linker, the analyte to be analyzed is more hydrophobic than in a case where the linker has an alkyl group in a part of the linker. And the possibility of causing non-specific interaction can be greatly reduced.
- the linker since the linker is partially composed of oligoethylene dioxide, it is easy to adjust the length from the disulfide group used for metal binding to the oligosaccharide chain bound to the amino terminal. Can be. As a result, a metal-sulfur bond can be formed efficiently without the disulfide group being affected by the oligosaccharide chain.
- m 1 , m, m °, m 4 , p 1 , ⁇ are each independently an integer of 1 or more and 6 or less).
- X of the linker compound has three or more hydrocarbon-derived chains, it is possible to introduce three or more units of sugar molecules onto the support via the linker compound. is there . Therefore, it is possible to obtain a sequence of sugar molecules with good reproducibility by controlling the spacing between sugar units of 3 units or more on the surface of the support, and thus to evaluate the biological activity of sugar molecules with good reproducibility. become.
- the ligand conjugate of the present invention is characterized in that a sugar molecule is introduced into an aromatic amino group of one of the above linker compounds.
- R ′ is hydrogen (H) or R.
- R is the formula (6-1) or the formula (6-6)
- the compound is an oligosaccharide-derived compound selected from Further, the ligand complex is specifically represented by the general formula (7) [0031] [Formula 17]
- R is hydrogen (H) or R.
- R is preferably an oligosaccharide selected from the formulas (6-1) and (6-6).
- the sugar molecules can be assembled and fixed.
- one ligand conjugate has three or more sugar molecules, it is possible to use one ligand conjugate without assembling the ligand conjugates on the surface of the support.
- three or more units of sugar molecules can be aggregated. Therefore, the biological activity of the sugar molecule can be measured with good reproducibility.
- a plurality of sugar molecules can be two-dimensionally arranged on the surface of the support with good reproducibility. Therefore, by using a support for protein analysis to which the ligand complex of the present invention is immobilized, the biological activity of the sugar molecule can be evaluated with good reproducibility.
- the method for producing a linker compound according to the present invention provides thiotate acid and an amine having three or more branched chains whose aromatic amino terminal is protected by a protective group.
- the method has an SS bond as a site that can be immobilized on the protein analysis support, and an aromatic amino group as a site into which a sugar molecule can be easily introduced.
- the linker compounds of the invention can be obtained.
- a method for producing a ligand conjugate of the present invention is characterized in that a reductive amination reaction is performed using the above-mentioned linker compound and a sugar molecule.
- the ligand conjugate of the present invention can be obtained by simply introducing a sugar molecule into a linker compound by a reductive amination reaction.
- sugar molecule any type of sugar molecule having a reducing end can be used.
- sugar molecule examples include those represented by the general formula (8)
- the method for introducing a sugar molecule of the present invention is characterized in that in order to solve the above-mentioned problems, a solution containing the ligand complex is brought into contact with a metal on the surface of a support.
- the S—S bond of the linker compound contained in the ligand complex is converted into a bond with a metal on the surface of the support, and a sugar chain as a ligand is formed on the surface of the support.
- a sugar chain as a ligand is formed on the surface of the support.
- the sugar molecules bound to the linker compound can be arranged on the surface of the support by a simple method of bringing the solution containing the ligand complex into contact with the support.
- the ligand carrier of the present invention is characterized in that the ligand complex is fixed on a support having a metal on the surface.
- the ligand complex can be firmly immobilized on the surface of the support via the metal-sulfur bond, so that a plurality of sugar molecules can be arranged on the surface of the support with good reproducibility. Can be provided. Therefore, the use of the above ligand carrier makes it possible to reproducibly observe the interaction between the sugar molecule contained in the ligand complex and a substance such as a protein that interacts with the sugar molecule. Quantitative evaluation of biological activity becomes possible.
- FIG. 1 is a schematic diagram showing an example of a synthesis route for a linker compound (a conjugate compound 15) according to the present invention.
- FIG. 2 is a schematic diagram showing an example of a synthesis route of a ligand conjugate (a conjugate 17) according to the present invention.
- FIG. 3 is a graph showing the binding behavior of bFGF to a chip on which Mono-GlcNS6S-IdoA2S-Glc is immobilized in the presence of heparin!
- FIG. 4 is a graph showing the inhibitory rate of heparin on the interaction of bFGF binding to a chip on which Tetra-GlcNS6S-IdoA2S-Glc is immobilized, respectively.
- FIG. 5 (a) is a graph showing the total reflection infrared absorption statistic of Tri-GlcNS6S-IdoA2S-Glc in which the mixing ratio in the solution was changed.
- FIG. 5 (b) is a graph showing the total reflection infrared absorption spectrum of Tetra-GlcNS6S-IdoA2S-Glc with a different mixing ratio in the solution.
- FIG. 6 (a) is a graph showing the relative strength of sulfate groups on the chip with respect to the mixing ratio of Tri-GlcNS6S-IdoA2S-Glc in the solution.
- FIG. 6 (b) is a graph showing the relative strength of sulfate groups on the chip with respect to the mixing ratio of Tetra-GlcNS6S-IdoA2S-Glc in the solution.
- FIG. 7 (a) A graph showing the result of observing the binding interaction of h-vWF by the SPR method when the mixing ratio of Mono-GlcNS6S-IdoA2S-Glc and Mono-Glc is 100Z0.
- FIG. 7 (b) is a graph showing the results of observing the binding interaction of h-vWF by SPR method when the mixing ratio of Tri-GlcNS6S-IdoA2S-Glc and Mono-Glc is 100Z0.
- FIG. 7 (c) A graph showing the results of observing the binding interaction of h-vWF by the SPR method when the mixing ratio of Tetra-GlcNS6S-IdoA2S-Glc and Mono-Glc is 100Z0.
- FIG. 8 (a) is a graph showing the result of observing the binding interaction of h-vWF by SPR method when the mixing ratio of Mono-GlcNS6S-IdoA2S-Glc and Mono-Glc is 20Z80.
- FIG. 8 (c) A graph showing the results of observing the binding interaction of h-vWF by the SPR method when the mixing ratio of Tetra-GlcNS6S-IdoA2S-Glc and Mono-Glc is 20Z80.
- FIG. 9 (a) is a graph in which the amount of binding obtained from the results shown in FIGS. 7 (a) and 8 (a) is plotted for each h-vWF concentration.
- FIG. 9 (b) is a graph in which the amount of binding obtained from the results shown in FIGS. 7 (b) and 8 (b) is plotted for each h-vWF concentration.
- FIG. 9 (c) is a graph in which the amount of binding obtained from the results shown in FIGS. 7 (c) and 8 (c) is plotted for each concentration of h-vWF.
- FIG. 14 is a schematic view showing one example of a synthesis route of a ligand conjugate (a conjugate 27) according to the present invention.
- FIG. 15 is a schematic diagram showing an example of a synthesis route for a linker compound (a compound 32) according to the present invention.
- FIG. 16 is a schematic diagram showing an example of a synthesis route for H N-TEG-NHBoc (Compound 30).
- FIG. 17 is a schematic diagram showing an example of a synthesis route of a ligand conjugate (a conjugated product 34) according to the present invention.
- the linker compound of the present invention comprises a support for protein analysis, such as a carrier for surface plasmon resonance (SPR) sensor chip affair-take mouth chromatography, and a sugar such as an oligosaccharide (hereinafter referred to as a sugar molecule). ) Is used to immobilize sugar molecules on the support. Therefore, it is necessary that the linker compound has, in the molecule, a site that can be fixed to the support and a site that can easily introduce a sugar molecule.
- a support for protein analysis such as a carrier for surface plasmon resonance (SPR) sensor chip affair-take mouth chromatography
- a sugar such as an oligosaccharide
- the above-described SPR affair-take mouth chromatography aims to specify and separate substances such as proteins that specifically interact with sugar molecules. Therefore, the above linker compound must have no non-specific interaction with substances such as proteins.
- the linker compound of the present invention may be used as a site that can be fixed to the above-mentioned support, as shown in the general formula (1) or (2), a disulfide bond (SS bond) have.
- the sulfur (S) of the disulfide bond forms a metal-sulfur bond with a metal such as gold (Au) coated on the surface of a support for protein analysis, and can be strongly bonded to the support. .
- the linker compound is used to arrange a plurality of sugar molecules two-dimensionally on the surface of a support for protein analysis and to control the distance between sugar chains of individual sugar molecules.
- the amino group (one NH group) of the above-mentioned aromatic amino group can be reduced with a sugar molecule such as an oligosaccharide.
- the reaction becomes a reactive group for introducing a sugar molecule into the linker compound. That is, the aldehyde group (one CHO group) or ketone group (one CRO group, R is a hydrocarbon group) generated by the equilibrium in the sugar molecule reacts with the amino group of the linker compound. Then, by successively reducing the Schiff base formed by this reaction, a sugar molecule can be easily introduced into the aromatic amino group.
- X in the general formula (1) or the general formula (2) has a plurality of aromatic amino groups into which a sugar molecule can be introduced by containing three or more hydrocarbon-derived chains as described above. It has a structure that is probably a divergent site. Since a sugar molecule such as an oligosaccharide is introduced into each aromatic amino group contained in the hyperbranched moiety, a linker having a structure represented by the general formula (1) or (2) is provided. Through one compound, a plurality of sugar molecules can be two-dimensionally arranged with good reproducibility on the surface of a support for protein analysis.
- the linker compound of the present invention has an oligoethylene oxide between a disulfide group and an aromatic amino group, as shown in the general formula (1) or (2).
- I have.
- a, b, d, and e may be each independently an integer of 0 or more and 6 or less.
- n is not limited as long as it is an integer of 1 to 6.
- X is a group in which two hydrocarbon-derived chains form one nitrogen ( A structure having two bifurcated structures bonded to N) may be provided.
- the two nitrogens in the two-branched structure are linked to one nitrogen (N), for example, via CO--CH to form a branched structure.
- X is a hyperbranched site with four hydrocarbon-derived chains Will have a structure.
- m 1 , m 2 , m 3 , and m 4 are not limited as long as they are integers of 1 or more and 6 or less. It may be the same integer.
- m 1 to m 4 are preferably the same integer, and particularly preferably 2 in terms of simplicity in producing the compound having the multi-branched site.
- p 1 and p 2 are not particularly limited as long as they are integers of 1 or more and 6 or less, and may be different integers or the same integer.
- p 1 and p 2 are preferably 1 and particularly preferably 1 from the viewpoint of simplicity of production.
- X having four hydrocarbon-derived chains represented by the general formula (3) may have a structure having oligoethylene oxide in each of the hydrocarbon-derived chains.
- an oligoethylene oxide is placed between CH and NH of each hydrocarbon-derived chain.
- It may be a structure having a side.
- X is, as shown in the general formula (4), the three hydrocarbon-derived chains are linked to one carbon (C) at the terminal opposite to the aromatic amino group.
- a structure having a coupled three-branch structure may be provided.
- the above-mentioned carbon having a three-branched structure is bonded to one nitrogen (N) via, for example, -C-N- to form a branched structure.
- N nitrogen
- X has a structure that is a hyperbranched site having three hydrocarbon-derived chains.
- q 1 , q, and q 3 are not limited as long as they are integers of 0 or more and 6 or less. All may be the same integer. Above all, in view of the production time of the ease of compound having the multi-the q 1 one q 3 is preferably is preferably tool particularly 2 be mutually the same integer. Further, r 1 , r 2 , and r 3 are not limited as long as they are integers of 0 or more and 6 or less, and may be mutually different integers, or some or all of them may be the same integers. Among these, from the viewpoint of simplicity of production, the above-mentioned r 1 -r 3 are preferably the same integer, and particularly preferably 1.
- u 1 , u 2 , and u 3 are not limited as long as they are integers of 0 or more and 6 or less, and may be mutually different integers, or some or all may be the same integers.
- the above u 1 —u 3 are preferably the same integer, and particularly preferably 1.
- t 1 , t 2 , and t 3 are not limited as long as they are integers of 0 or more and 6 or less, and may be different integers, or some or all may be the same integers.
- t 1 , t 2 , and t 3 are integers of 1 to 6 It is preferable that From the viewpoint of simplicity of production, the above-mentioned t 1 -t 3 are preferably mutually the same integer, particularly preferably 4.
- X has a structure that is a multi-branched portion in which a plurality of the hydrocarbon-derived chains are bonded to form a branched structure by atoms such as carbon and nitrogen.
- the plurality of hydrocarbon-derived chains contained in X is preferably the same, but may have different structures as long as they have an aromatic amino group at the terminal. .
- the linker compound having the structure represented by the general formula (1) or the general formula (2) has an S--S bond capable of binding to a support for protein analysis, It has an amino group capable of binding to a sugar molecule such as an oligosaccharide chain. Therefore, the linker compound is immobilized on the support for protein analysis by a metal-sulfur bond such as an Au—S bond, so that the sugar molecule is firmly attached to the support via the linker compound. It can be easily and easily combined.
- the linker compound has a multi-branched site, and has an aromatic amino group at each end of the multi-branched site. Therefore, by using a ligand complex (described later) in which a sugar molecule is introduced into the linker compound, sugar molecules can be efficiently assembled on the surface of the support. In addition, since it has a hyperbranched site, when a ligand complex containing a linker compound is bound to the surface of a support, it is possible to two-dimensionally arrange a plurality of sugar molecules with good reproducibility. it can.
- the above-mentioned linker compound can substantially ignore the influence of non-specific interaction with a protein. Therefore, by using the linker compound of the present invention, the biological activity of the sugar molecule can be evaluated with good reproducibility.
- the linker compound has an oligoethylene oxide between the disulfide group and the aromatic amino group as shown in the general formula (1) or (2). .
- non-specific hydrophobic interactions can be minimized, and the length of the metal bond to the disulfide group can be easily adjusted to form a metal sulfur bond efficiently. Can do.
- the linker compound is produced by the following production method. That is, the above-mentioned linker compound is subjected to a condensation reaction between a thioexoacid and an aminy conjugate containing a multi-branched structure having three or more branched chains whose aromatic amino group terminals are protected by protective groups. It is produced by deprotecting the protecting group at the terminal of the aromatic amino group.
- the thiotate acid is represented by the following general formula (10)
- the amine compound is not particularly limited as long as it contains a branched chain having an aromatic amino group terminal protected by a protecting group.
- the amine compound corresponds to a multibranched site of the linker compound described above. Including the structure to do.
- the above-mentioned branched chain has the same structure as that of the above-mentioned hydrocarbon derivative chain except that it has an aromatic amino group terminal protected by a protecting group instead of the aromatic amino group contained in the above-mentioned hydrocarbon derivative chain.
- the above-mentioned branched chain is a hydrocarbon chain composed of carbon and hydrogen, in which a part of carbon and hydrogen may be replaced by another atom or substituent. More specifically, the branched chain has an aromatic amino group terminal protected by a protecting group, and a part of a carbon-carbon bond (C-C bond) which is a main chain structure of a hydrocarbon chain. It may be replaced by a carbon-nitrogen bond (C-N bond) or a carbon-oxygen bond (C-O bond).
- the protecting group is a substituent introduced so that the amino group of the aromatic amino group is not reacted by the condensation reaction.
- a protecting group is not particularly limited as long as it is not affected when the protecting group of the secondary amino group is deprotected.
- the protecting group include a t-butoxycarbol group (a COOC (CH) group; a Boc group).
- aminy conjugate examples include the following general formula (11)
- the above-mentioned linker compound has a structure in which an oligoethylene oxide is provided in a part of the linker as described above, in the production method, a substance containing the oligoethylene oxide structure is used as a raw material. It is preferable to use them.
- this raw material include bis [2- (2-hydroxyethoxy) ethyl] ether (compound 1 of the example) and compounds having different molecular weights.
- Commercially available polyethylene glycol (Mw: 200, 300, 400, 600, 1000) manufactured by Sigma, among which the degree of polymerization is completely controlled, that is, the length is controlled. It is preferred to use bis [2- (2-hydroxyethoxy) ethyl] ether (Compound 1 of the example) because it has a modified structure.
- the “ligand complex” shall mean a compound obtained by introducing a sugar molecule into an aromatic amino group of the linker compound.
- the amino group of the linker compound reacts with the aldehyde group or ketone group generated by the equilibrium in the sugar molecule, and the Schiff base formed by this reaction is subsequently reduced, whereby the aroma is obtained.
- a sugar molecule can be introduced into an aromatic amino group. That is, by the reductive amination reaction, the linker compound and the sugar molecule are bonded.
- the sugar molecule contained in the ligand conjugate of the present invention is not particularly limited as long as it is a reducing sugar having a reducing end, and any kind can be used.
- Specific examples of the sugar molecules include monosaccharides such as glucose, galactose, and mannose; and oligosaccharides such as maltose and ratatose, in which the number of linked sugars is a disaccharide-to-ten-saccharide, and sulfated oligosaccharides described below. And monosaccharides and oligosaccharides that have a sugar number of 11 or more, and include polysaccharides such as heterophosphorus, chondroitin sulfate, and heparan sulfate.
- a sulfated polysaccharide heparin known to have anticoagulant activity has the following general formula (8)
- GlcNS6S-IdoA2S Having a specific partial disaccharide structure (referred to as "GlcNS6S-IdoA2S") represented by the following formula, wherein glucose is introduced into a hydroxyl group at the reducing end of the sulfated oligosaccharide.
- the above oligosaccharides and polysaccharides may be monooligosaccharides having the same monosaccharide molecular force, or complex saccharides composed of various monosaccharide molecules or derivatives thereof, which may be single polysaccharides.
- Complex polysaccharides containing monosaccharide molecules, derivatives thereof, and oligosaccharides may also be used.
- any of the above sugar molecules may be various natural sugars obtained by isolation and purification from the natural world, or artificially synthesized sugars.
- the ligand conjugate of the present invention has a structure represented by the general formula (5).
- the ligand conjugate having the structure represented by the general formula (5) is represented by the general formula (2), and X has the structure represented by the general formula (3). It is obtained by introducing a sugar molecule into a linker compound.
- the saccharide molecule is not limited as long as it is a reducing saccharide having a reducing terminal, but is preferably selected from the general formula group (9) and the general formula (12). Since X represented by the general formula (3) has a structure having four hydrocarbon-derived chains, the ligand complex having the structure represented by the general formula (5) Is a compound in which four or more sugar molecules are bonded to the above linker compound.
- m 1 - m 4 are formula (3) m 1 in - similarly to m 4, is not limited as long as 1 to 6.
- the integers differ by an integer from one another Some or all of them may be the same integer.
- n is not particularly limited as long as it is an integer of 1 or more and 6 or less.
- R ′ may be a compound derived from hydrogen (H) or an oligosaccharide.
- the ligand conjugate of the present invention has a structure represented by the general formula (7).
- the ligand conjugate having the structure represented by the general formula (7) is X is obtained by introducing a sugar molecule into a linker compound having the structure represented by the general formula (4), wherein X is represented by the general formula (1).
- the sugar molecule is not limited as long as it is a reducing sugar having a reducing end, but is preferably selected from general formula group (9) and general formula (12). Since X represented by the general formula (7) has a structure having three hydrocarbon-derived chains, the ligand complex having the structure represented by the general formula (7) Is a compound in which three or more sugar molecules are bonded to the above linker compound.
- the ligand complex contains a linker compound and a sugar molecule
- the ligand complex can be formed on the surface of the support for protein analysis by the S-S bond in the linker compound. It can be bonded to a metal by a metal sulfur (S) bond, for example, a gold sulfur (Au—S) bond.
- S metal sulfur
- Au—S gold sulfur
- a ligand carrier by, for example, two-dimensionally arranging a plurality of sugar molecules on the surface of a support for protein analysis with good reproducibility, and using the ligand carrier. This makes it possible to evaluate the biological activity of the sugar molecule with good reproducibility.
- a metal such as Cu, Ag, and Pt can be used as the metal on the surface of the support.
- Au is preferably used as the metal on the surface of the support.
- the above-mentioned ligand complex has oligoethylene oxide in a part of the linker.
- non-specific hydrophobic interactions can be minimized, and the length up to the disulfide group used for metal bonding can be easily adjusted, so that metal-sulfur bonds can be formed efficiently.
- the present invention also includes a ligand carrier obtained by immobilizing the ligand complex of the present invention on the surface of the support via a metal-sulfur bond.
- This ligand carrier is not limited to the use of protein analysis, and can be used for analysis of substances other than proteins in order to examine the interaction with sugar molecules.
- each S atom of the S--S bond of the ligand complex is formed on the surface of the support.
- the ligand complex is introduced to the surface of the support by binding to the metal by a metal-sulfur bond.
- a support for protein analysis is added to the ligand complex solution at a predetermined time.
- the solvent used for the ligand complex solution is not particularly limited.
- the immersion time may be about 0.5 hours to 12 hours, and the injection concentration may be about 1 ⁇ -ImM.
- the ligand complex of the present invention since the ligand complex of the present invention has an SS bond, it can be easily immobilized on the surface of a support for protein analysis, and can be immobilized on the support. Sugar molecules can be easily introduced.
- the ligand carrier of the present invention can be used for analyzing interaction between a sugar molecule and another substance such as a protein. Specifically, the above-mentioned ligand carrier can be applied to SPR measurement, affinity-take mouth chromatography, and the like.
- a ligand carrier obtained by immobilizing the ligand complex of the present invention is used on a support on which a metal thin film such as a gold thin film is deposited, and the ligand carrier and the protein are brought into contact with each other. If the resonance angle is measured using a plasmon resonance device, the binding behavior between the ligand carrier and the protein can be observed.
- the support (sensor chip) used for the SPR measurement for example, glass, plastic, or the like can be used, and glass is particularly preferably used.
- the contact between the ligand carrier and the protein may be performed, for example, by flowing a solution of the protein in a running buffer to the surface of the ligand carrier. Examples of the running buffer include a phosphate buffer solution.
- the ligand carrier of the present invention has the ligand complex described above, a plurality of sugar molecules are two-dimensionally arranged on the support surface with good reproducibility. Therefore, the biological activities of sugar molecules can be observed with good reproducibility, the structure of sugar molecules can be elucidated, and the biological activity of sugar molecules can be quantified. Evaluation can be performed.
- a sensor chip having a sugar chain immobilized thereon as the ligand carrier of the present invention can be used, for example, for the following SPR measurement. That is, the first sensor chip in which the first sugar molecule is immobilized on the surface of the support, and the second sugar molecule having a terminal structure different from that of the first sugar molecule are immobilized on the surface of the support. The difference between the detection result of the SPR measurement obtained by using the first sensor chip and the detection result of the SPR measurement obtained by using the second sensor chip using the second sensor chip And the interaction of sugar molecules can be observed.
- These sensor chips may use a ligand complex having different sugar molecules immobilized thereon.
- the sugar molecules to be compared include, for example, ratatose and glucose, maltose and glucose, kojibiose and glucose, and the like. Although two sensor chips are used here, more sensor chips having different types of sugar molecules to be introduced may be used. In addition, the terminus of the sugar molecule is the side not fixed to the sensor chip.
- the SPR measurement a protein or the like that specifically acts on the first sugar molecule is used, the measurement conditions are kept constant, and the SPR measurement is applied to the two sensor chips, and the resonance angle of the two is observed. By detecting the difference between the two resonance angles, it can be measured as a specific interaction between a sugar molecule and a protein or the like.
- the substance whose interaction with a sugar molecule is observed is not limited to a protein.
- the force simultaneously measured by two types of sensor chips is not limited to this.
- the force may be measured by measuring two or more types of sensor chips, or may not be measured simultaneously.
- a sensor chip in which a sugar molecule is not introduced into at least one sensor chip may be used.
- one obtained by fixing only one linker compound may be used.
- the measurement can be performed using at least two sensor chips in which a ligand conjugate having the same structure except for the sugar molecule is immobilized.
- the difference in the magnitude of the interaction measured in the above is observed as being due to the sugar molecule. Therefore, by using the above measurement method, it is possible to reduce the non-specific interaction between a portion other than the sugar molecule and another substance and to observe the specific interaction between the sugar molecule and another substance. Can be. [0098] ⁇ Example>
- linker compounds according to the present invention that is, in the general formula (2), n is 4, X is represented by the general formula (3), and p 1 and p 2 are 1
- a linker compound having a structure in which m 1 , m 2 , m 3 , and m 4 are 2 was synthesized by the following procedure.
- Figure 1 shows the process of synthesizing this linker compound (Compound 15).
- the numbers attached to the respective compounds correspond to the numbers described in FIG.
- an ester compound (compound 3) was synthesized in a yield of 40%.
- the compound 3 was reacted with p-toluenesulfuryl chloride in the presence of pyridine in DMAP in dichloromethane to give a tosyl compound (compound 4) in a yield of 78%.
- Compound 4 was reacted with sodium azide compound in N, N-dimethylformamide to give an azide form (a compound 5) in a yield of 90%.
- the NMR ⁇ vector was measured using a JEOL-JNM-Lambda-500 NMR spectrometer, a JEOL JNM-GSX400 NMR spectrometer and a JEOL EX-270 NMR spectrometer. Chemical shifts were expressed as ⁇ values using tetramethylsilane as a reference substance in the case of CDC1.
- CD 0D and DMSO-d are expressed as ⁇ values based on the chemical shift of the remaining solvent protons.
- Mass spectrometry was measured using AppliedBiosystems, Mariner TM.
- ATR-FT-IR measurement a device equipped with a one-time reflection ATR accessory device (MIRacle Ge prism) on Shimadzu, IRPrestige-21 was used. The same sensor chip used for SPR measurement was used for ATR-FT-IR measurement.
- Silica gel 60 No. 9385 (Merck) was used for medium pressure ram silica gel chromatography, and Silica gel 60 F254 (Merck) was used for thin layer silica gel chromatography.
- the anhydrous dichloromethane used was distilled under a nitrogen stream using calcium hydride as a desiccant.
- Other dehydrated solvents were purchased and used from Kanto-Danigaku Co., Ltd.
- the other reagents and solvents were basically of special grade.
- the azide compound 5 (614 mg, 2.01 mmol) was dissolved in 24 ml of methanol, and 4.3 ml of IN NaOH was added at 0 ° C under light shielding, followed by stirring at room temperature for 21 hours.
- the reaction solution was concentrated under reduced pressure, and the concentrated residue was diluted with chloroform.
- the organic layer was washed once with saturated saline and dried over anhydrous magnesium sulfate. The drying agent was removed by filtration and concentrated under reduced pressure to obtain Compound 6 (549 mg, yield: 90%) as a colorless liquid.
- N-Bocaminobenzoic acid derivative (3.33 g, 14.0 mmol) and HOBt (1.93 g, 14.3 mmol) were suspended in anhydrous dichloromethane (60 ml), and the mixture was stirred at 0 ° C for 15 minutes under an argon atmosphere.
- a solution of EDC-HC1 (2.87 g, 15.0 mmol) dissolved in anhydrous dichloromethane (30 ml) was heated and stirred for 50 minutes.
- Diethylenetriamine (0.79 ml, 7.00 mmol) was added to this solution, and the mixture was stirred overnight at room temperature under light shielding to obtain white crystals.
- the white crystals were collected by filtration and recrystallized from methanol to give Compound 10 (3.53 g, yield: 92.9%) as white crystals.
- the compound 12 is an n-force by general formula (11) is p 1, p 2 is 1, Amini that m 1, m 2, m 3 , m 4 has a structure which is 2 It is a dagger.
- n 4 in the general formula (2)
- X is represented by the general formula (3)
- p 1 and p 2 are 1
- m 1 and m 2 , m 3 , and m 4 are 2.
- n 4
- p 1 and p 2 are 1, m 1 , m 2 , m 3 , m 4 was 2
- R ′ was hydrogen (H)
- R was a ligand conjugate having a structure derived from an oligosaccharide represented by the general formula (12), which was synthesized by the following procedure.
- Figure 2 shows the chemical reaction formula for this synthesis.
- the compound 17 was subjected to 1 H-NMR (400 MHz, DO) measurement by the method described in Example 1.
- This compound 17 is a compound represented by the general formula (5), wherein n is 4, p 1 and p 2 are 1, m 1 , m 2 , m 3 , and m 4 are 2, and R Is a hydrogen (H), and R is an oligosaccharide-derived compound represented by the general formula (6-3).
- Another ligand complex is a ligand complex described in JP-A-2004-157108, which is a ligand complex represented by the following general formula (14).
- this ligand complex is referred to as “Tri-GlcNS6S-IdoA2S-Glc”. JP 2004-157108 is not disclosed as of the priority date of the present application.
- Example 3-1 the specific interaction between the chip having the disaccharide structure (GlcNS6S-IdoA2S) represented by the general formula (8) immobilized thereon and the heterozygous protein was determined. To confirm, an inhibition experiment was performed. That is, whether an inhibitor that inhibits the binding between the helin-binding protein and the GlcNS6S-IdoA2S structure was coexisted, and it was examined whether or not the binding of the henin-binding protein to the chip was inhibited.
- bFGF heparin-binding protein
- FGF-2 vascular endothelial cells and fibroblasts
- heparin analogues on the cell surface Interacts with heparan sulfate, which is a quality substance, and expresses biological activity. It has been reported that the minimum binding unit required for binding to bFGF is a pentasaccharide represented by the following general formula (15) (references: M. Maccarana, B. Casu & U. Lindahl, J. Biol. Chem. 268, 8857, 1993).
- the above structure includes a structure in which the 6th position of dalcosamine is sulfated.
- bFGF was selected as a protein for observing the interaction with the GlcNS6S-IdoA2S structure.
- Fig. 3 shows the binding behavior of bFGF to a chip on which Mono-GlcNS6S-IdoA2S-Glc was immobilized. From this figure, it was confirmed that the binding of bFGF to the chip on which Mono-GlcNS6S-IdoA2S-Glc was immobilized was reduced in a concentration-dependent manner to the concentration of H-. That is,
- IC 2.5 for the chip on which Mono-GlcNS6S-IdoA2S-Glc was immobilized.
- the IC value of the chip immobilized with Mono-GlcNS6S-IdoA2S-Glc is the IC value of the other two types of chips.
- a linker compound in which Tri-GlcNS6S-IdoA2S-Glc or Tetra-GlcNS6S-IdoA2S-Glc is bound to a molecule having no sugar chain (a non-sugar chain linker-linking compound, hereinafter referred to as Mono-Glc )
- Mono-Glc a linker compound in which Tri-GlcNS6S-IdoA2S-Glc or Tetra-GlcNS6S-IdoA2S-Glc is bound to a molecule having no sugar chain
- FIG. 5B shows the total reflection spectrum of Tri-GlcNS6S-IdoA2S-Glc
- FIG. 5 (b) shows the total reflection spectrum of Tetra-GlcNS6S-IdoA2S-Glc when the mixing ratio in the solution was changed.
- Example 3-3 Examination of influence of relative density of sugar chain on interaction with h-vWF] Subsequently, relative density of sulfated disaccharide, which is a ligand on the chip surface, was determined by comparing protein with protein. The effect on the interaction with was examined. Here, the interaction with human plasma-derived vWF (hereinafter referred to as h-vWF) was analyzed.
- h-vWF human plasma-derived vWF
- Tri-GlcNS6S—IdoA2S—Glc ⁇ Tetra—GlcNS6S—IdoA2S—Glc) and Mono—Glc were mixed at 100/0 and 20/80, respectively.
- Interaction with vWF was observed by the SPR method.
- the procedure of measurement by the SPR method will be described.
- SPR670 manufactured by Nippon Laser Electronics Co., Ltd.
- 2 nm chromium was deposited as an adhesive layer on a 13 x 20 x 0.7 mm glass substrate, and a 50 nm gold thin film was deposited thereon (manufactured by Nippon Laser Electronics Co., Ltd.).
- the sample was placed in a UV ozone cleaner (NL-UV253, manufactured by Japan Laser Electronics Co., Ltd.) and irradiated with ultraviolet rays for 30 minutes to wash the chip surface with ozone.
- UV ozone cleaner NL-UV253, manufactured by Japan Laser Electronics Co., Ltd.
- Mono-GlcNS6S-IdoA2S-GlcZMono-Glc was dissolved in methanol solution (0. ImM), 50 ⁇ l of this solution was taken into a PTFE cell, and sealed with parafilm. The PTFE cell equipped with the chip was gently shaken overnight at room temperature on a Bio Dancer (New Brunswick Scientific).
- the chip was washed six times with methanol, washed once with water, and then again once with methanol and then water. After air drying, it was mounted on the SPR670 sensor chip cartridge. After the chip surface was sufficiently equilibrated with a running buffer, the gold film was irradiated with a laser beam, and the change in surface plasmon resonance angle observed at that time was observed.
- a running buffer an isotonic phosphate buffer solution (PBS) having a pH of 7.4 was used. All SPR measurements were performed at a temperature of 25 ° C.
- bFGF was manufactured by STRATHMANN BIOTEC AG (Recombiant Human FGF-basic, MW; 17000, Lot No .; 471120), and h-vWF was A product of CALBIOCHEM (von Willebrand Factor, Human Plasma, MW; 270000 (converted to Monomer Unit), Lot No .; B41632) was used.
- Figures 7 (a)-(c) show the above three ligand complexes (Mono-GlcNS6S-IdoA2S-Glc,
- FIGS. 9 (a) and 9 (c) show plots of the binding amount at which the strength was also obtained for each concentration of h-vWF.
- (a) is for Mono-GlcNS6S-IdoA2S-Glc
- (b) is for
- FIG. 9 also shows the results of calculating the curve force and the dissociation constant (K) of each graph.
- h-vWF adopts a multimeric structure, so that there are multiple henolin-binding domains, and the dissociation rate is remarkably slowed by the effect, and the difference in distance between sugar chains is reflected in the dissociation constant. It was thought that it was not done.
- Example 3-4 Investigation of the Effect of the Relative Density of Sugar Chains on the Interaction with Proteins
- Escherichia coli derived from Escherichia coli having only A1 / lepe moiety having one henolin binding domain
- rhvWF-Al recombinant human vWF partial protein
- FIGS. 10 to 12 show the results of measuring the binding interaction with the chip by changing the rhvWF-Al concentration.
- FIG. 10 (b) shows the case where Mono-GlcNS6S-IdoA2S-GlcZ was used.
- Table 1 summarizes the dissociation constant, association constant, association rate constant, and dissociation rate constant calculated from these results.
- the dissociation constant K & 710 and the binding constant: 1 ⁇ (k
- binding rate constant k
- dissociation rate constant k
- Tetra-GlcNS6S-IdoA2S-Glc has a sugar chain cluster structure in which the distance between sulfated oligosaccharide chains is controlled in the molecule, so that the density of sugar chains immobilized on the chip is relatively reduced. It is thought that it is hard to be affected by this. [0167] In other words, in the interaction with rhvWF-Al, in the chip in which Mono-GlcNS6S-IdoA2S-Glc was immobilized, the binding strength decreased when the relative sugar chain immobilization density on the chip was reduced. It was confirmed that it would. In contrast, Tri-GlcNS6S-IdoA2S-Glc and
- FIG. 13 shows the process of synthesizing this linker compound (I-Rid Compound 26).
- FIG. 14 shows a process of synthesizing a ligand complex (compound 27) from the linker compound (compound 26).
- the numbers appended to the respective compounds correspond to the numbers shown in FIGS.
- the JOEL-Delta600 Spectrometer was used for NMR spectrum measurement. Chemical shifts are expressed as ⁇ values with reference to tetramethylsilane (0.00 ppm) for CDC1.
- FIG. 15 shows a process of synthesizing the linker compound (the compound 32).
- FIG. 16 shows a process of synthesizing the compound 30 used in the process of synthesizing the linker one compound (the compound 32).
- FIG. 17 shows a process of synthesizing a ligand conjugate (compound 34) from the linker compound (diagonal compound 32).
- the numbers added to the respective compounds correspond to the numbers shown in FIGS. 15, 16, and 17. Hit.
- the JOEL-Delta600 Spectrometer was used for NMR spectrum measurement. Chemical shifts are expressed as ⁇ values with reference to tetramethylsilane (0.00 ppm) for CDC1.
- the linker compound of the present invention has an aromatic amino group terminal as a site into which three or more sugar molecules can be introduced.
- it has an S—S bond as a site that can be bonded to a support for protein analysis such as a carrier for surface plasmon resonance (SPR) sensor chip perforated-mouth chromatography.
- a disulfide group and an aromatic amino group are used so that nonspecific hydrophobic interaction can be minimized and the length up to the disulfide group used for metal bonding can be easily adjusted. And oligoethylene oxide between them.
- the use of the linker compound has an effect that three or more units of sugar molecules can be two-dimensionally arranged with good reproducibility on the surface of the support.
- the linker compound reproduces the biological activities of sugar molecules when observing the interactions between sugar molecules and proteins. It is possible to evaluate sexually. Furthermore, a metal sulfur bond can be efficiently formed.
- the ligand conjugate of the present invention is obtained by introducing a sugar molecule into the above linker compound.
- a linker compound capable of controlling the distance between sugar chains on the sensor chip surface and two-dimensionally arranging oligosaccharides with good reproducibility, and a sugar molecule in the linker compound
- the ligand complex to be introduced can be obtained.
- the linker compound and the ligand complex are very useful for practical use of an oligosaccharide chip and for general use.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/588,612 US7838549B2 (en) | 2004-02-05 | 2005-02-04 | Linker compound, ligand conjugate, and production methods thereof |
CN2005800041123A CN1918143B (zh) | 2004-02-05 | 2005-02-04 | 连接子化合物、配体络合物和它们的制备方法 |
JP2005517757A JP4628960B2 (ja) | 2004-02-05 | 2005-02-04 | リンカー化合物及びリガンド複合体、並びにそれらの製造方法 |
CA2559962A CA2559962C (en) | 2004-02-05 | 2005-02-04 | Linker compound, ligand complex and process for producing them |
DE602005024779T DE602005024779D1 (de) | 2004-02-05 | 2005-02-04 | Linkerverbindung, ligandenkomplex und verfahren zu deren herstellung |
EP05709791A EP1731517B1 (en) | 2004-02-05 | 2005-02-04 | Linker compound, ligand complex and process for producing them |
IL177220A IL177220A0 (en) | 2004-02-05 | 2006-08-01 | Linker compound, ligand conjugate, and production methods thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-029562 | 2004-02-05 | ||
JP2004029562 | 2004-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005075453A1 true WO2005075453A1 (ja) | 2005-08-18 |
WO2005075453A9 WO2005075453A9 (ja) | 2006-08-31 |
Family
ID=34835955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001726 WO2005075453A1 (ja) | 2004-02-05 | 2005-02-04 | リンカー化合物及びリガンド複合体、並びにそれらの製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7838549B2 (ja) |
EP (1) | EP1731517B1 (ja) |
JP (1) | JP4628960B2 (ja) |
CN (1) | CN1918143B (ja) |
CA (1) | CA2559962C (ja) |
DE (1) | DE602005024779D1 (ja) |
IL (1) | IL177220A0 (ja) |
TW (1) | TWI346098B (ja) |
WO (1) | WO2005075453A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100740071B1 (ko) | 2006-03-10 | 2007-07-16 | 한불화장품주식회사 | 리포익산 유도체 및 이를 함유한 피부외용제 조성물 |
JPWO2005077965A1 (ja) * | 2004-02-18 | 2007-10-18 | 独立行政法人科学技術振興機構 | 糖鎖リガンド複合体、およびそのリガンド複合体を用いたタンパク質の分析方法 |
JP2011505572A (ja) * | 2007-12-04 | 2011-02-24 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 標識粒子を用いた流体内分子測定方法 |
US9239329B2 (en) | 2006-12-18 | 2016-01-19 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
WO2017053769A1 (en) | 2015-09-25 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as p2y14 receptor antagonists |
JP2019077686A (ja) * | 2017-10-26 | 2019-05-23 | 国立大学法人 鹿児島大学 | Tlrリガンド固定化ナノ粒子 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101100803B1 (ko) * | 2009-04-24 | 2011-12-29 | 서울과학기술대학교 산학협력단 | 리포아마이드가 결합된 고분자화합물과 이의 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003083969A (ja) * | 2001-09-14 | 2003-03-19 | Japan Science & Technology Corp | リンカー化合物およびリガンド並びにオリゴ糖鎖の固定化方法および蛋白質分析用の支持体 |
US20030059865A1 (en) * | 2001-09-05 | 2003-03-27 | Nelson Deanna Jean | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
JP2003190568A (ja) | 2001-12-28 | 2003-07-08 | Sun Corp | 遊技場管理装置 |
JP2004157108A (ja) | 2002-09-09 | 2004-06-03 | Japan Science & Technology Agency | リンカー化合物及びリガンド、並びにそれらの製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3834607B2 (ja) | 2000-06-28 | 2006-10-18 | 国立大学法人大阪大学 | オリゴ糖鎖・フェニレンジアミン複合化合物の製造方法、オリゴ糖鎖集合化用リンカー化合物、リンカー化合物により集合化したオリゴ糖鎖・フェニレンジアミン複合化合物 |
-
2005
- 2005-02-04 CA CA2559962A patent/CA2559962C/en not_active Expired - Fee Related
- 2005-02-04 US US10/588,612 patent/US7838549B2/en not_active Expired - Fee Related
- 2005-02-04 DE DE602005024779T patent/DE602005024779D1/de active Active
- 2005-02-04 EP EP05709791A patent/EP1731517B1/en not_active Expired - Fee Related
- 2005-02-04 CN CN2005800041123A patent/CN1918143B/zh not_active Expired - Fee Related
- 2005-02-04 JP JP2005517757A patent/JP4628960B2/ja not_active Expired - Fee Related
- 2005-02-04 WO PCT/JP2005/001726 patent/WO2005075453A1/ja active Application Filing
- 2005-02-05 TW TW094103908A patent/TWI346098B/zh not_active IP Right Cessation
-
2006
- 2006-08-01 IL IL177220A patent/IL177220A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059865A1 (en) * | 2001-09-05 | 2003-03-27 | Nelson Deanna Jean | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
JP2003083969A (ja) * | 2001-09-14 | 2003-03-19 | Japan Science & Technology Corp | リンカー化合物およびリガンド並びにオリゴ糖鎖の固定化方法および蛋白質分析用の支持体 |
JP2003190568A (ja) | 2001-12-28 | 2003-07-08 | Sun Corp | 遊技場管理装置 |
JP2004157108A (ja) | 2002-09-09 | 2004-06-03 | Japan Science & Technology Agency | リンカー化合物及びリガンド、並びにそれらの製造方法 |
Non-Patent Citations (4)
Title |
---|
ARANO A. ET AL: "Heparin Bubun Kozo o Yusuru Cluster-Ka Oligo-tosa Rigand no Gosei to Chip Technology eno Oyo.", THE CHEMICAL SOCIETY OF JAPAN KOEN YOKOSHU., vol. 82, 2002, pages 137, XP002991264 * |
ARANO A. ET AL: "Ryusan Oligo-to o Shugoka Shite Koteika shita Sugar Chip no Chosei to SPR-ho eno Oyo.", THE JAPANESE SOCIETY OF CARBOHYDRATE RESEARCH NENKAI YOSHISHU., vol. 24, 2003, pages 127, XP002991263 * |
See also references of EP1731517A4 |
SUDA Y. ET AL: "Oligo-tasa no Nano Level Kino Kaiseki System no Kaihatsu.", THE JAPANESE SOCIETY OF CARBOHYDRATE RESEARCH NENKAI YOSHITSU., vol. 24, 2003, pages 36, XP002991262 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005077965A1 (ja) * | 2004-02-18 | 2007-10-18 | 独立行政法人科学技術振興機構 | 糖鎖リガンド複合体、およびそのリガンド複合体を用いたタンパク質の分析方法 |
JP4800771B2 (ja) * | 2004-02-18 | 2011-10-26 | 独立行政法人科学技術振興機構 | 糖鎖リガンド複合体、およびそのリガンド複合体を用いたタンパク質の分析方法 |
KR100740071B1 (ko) | 2006-03-10 | 2007-07-16 | 한불화장품주식회사 | 리포익산 유도체 및 이를 함유한 피부외용제 조성물 |
WO2007105854A1 (en) * | 2006-03-10 | 2007-09-20 | Han-Bul Cosmetics Co., Ltd. | Novel lipoic acid conjugated compounds and skin external applications containing thereof |
US9239329B2 (en) | 2006-12-18 | 2016-01-19 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
JP2011505572A (ja) * | 2007-12-04 | 2011-02-24 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 標識粒子を用いた流体内分子測定方法 |
WO2017053769A1 (en) | 2015-09-25 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as p2y14 receptor antagonists |
US10683277B2 (en) | 2015-09-25 | 2020-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as P2Y14 receptor antagonists |
JP2019077686A (ja) * | 2017-10-26 | 2019-05-23 | 国立大学法人 鹿児島大学 | Tlrリガンド固定化ナノ粒子 |
Also Published As
Publication number | Publication date |
---|---|
DE602005024779D1 (de) | 2010-12-30 |
WO2005075453A9 (ja) | 2006-08-31 |
TWI346098B (en) | 2011-08-01 |
CN1918143B (zh) | 2012-01-11 |
CA2559962C (en) | 2011-03-15 |
CA2559962A1 (en) | 2005-08-18 |
EP1731517B1 (en) | 2010-11-17 |
CN1918143A (zh) | 2007-02-21 |
IL177220A0 (en) | 2006-12-10 |
TW200530151A (en) | 2005-09-16 |
JP4628960B2 (ja) | 2011-02-09 |
US20070213523A1 (en) | 2007-09-13 |
US7838549B2 (en) | 2010-11-23 |
EP1731517A1 (en) | 2006-12-13 |
EP1731517A4 (en) | 2007-09-26 |
JPWO2005075453A1 (ja) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005075453A1 (ja) | リンカー化合物及びリガンド複合体、並びにそれらの製造方法 | |
JP5339310B2 (ja) | 糖鎖リガンド複合体、およびそのリガンド複合体を用いたタンパク質の分析方法 | |
JP3970811B2 (ja) | リンカー化合物及びリガンド、並びにそれらの製造方法 | |
Csíki et al. | Synthesis of glycosaminoglycan oligosaccharides. Part 4: Synthesis of aza-l-iduronic acid-containing analogs of heparan sulfate oligosaccharides as heparanase inhibitors | |
JP4430344B2 (ja) | 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法 | |
Duong et al. | Synthesis of chimera oligopeptide including furanoid β-sugar amino acid derivatives with free OHs: mild but successful removal of the 1, 2-O-isopropylidene from the building block | |
KR100877644B1 (ko) | 링커 화합물 및 리간드 복합체, 및 그것들의 제조 방법 | |
JP2007127616A (ja) | 機能性有機分子固定化体及びそれを用いたセンサー、検体の検出方法及び検出装置、並びに機能性有機分子 | |
CA2213256C (en) | Fluorine-substituted ganglioside gm3 derivative and intermediates therefor | |
JP4364853B2 (ja) | リンカー化合物およびリガンド並びにオリゴ糖鎖の固定化方法および蛋白質分析用の支持体 | |
CN100398554C (zh) | 链化合物和配体、及其制备方法 | |
JP2005239632A (ja) | 重合性双頭型糖脂質、そのチューブ状凝集体及びその重合体 | |
Huang | I: Study of protein-carbohydrate interaction on carbohydrate arrays. II: Synthesis of analogues of sphingosine base, nitric oxide donors and HDAC inhibitors | |
JP2003252835A (ja) | オリゴエチレングリコール脂質 | |
Rauthu | Design of selective ligands for conjugate drug targeting to human serum albumin (HSA) through cysteine-34 and β-D-galactopyranoside inhibitors towards galectins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 177220 Country of ref document: IL Ref document number: 2559962 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580004112.3 Country of ref document: CN Ref document number: 2005517757 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005709791 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067018117 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005709791 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067018117 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10588612 Country of ref document: US Ref document number: 2007213523 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10588612 Country of ref document: US |